Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Stefanski

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Transplantation and Cellular Therapy|November 1, 2023
Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell TransplantationLacey S Williams, Kirsten M Williams, Nancy Gillis, et al.
American Journal of Hematology|January 6, 2023
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemiaGuru Subramanian Guru Murthy, Brent R Logan, Stephanie Bo-Subait, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
The Journal of Clinical Investigation|April 5, 2017
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host diseaseDanny W Bruce, Heather E Stefanski, Benjamin G Vincent, et al.
Bone Marrow Transplantation|March 5, 2024
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Bone Marrow Transplantation|June 21, 2024
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Blood Cancer Discovery|January 12, 2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaMichael A Pulsipher, Xia Han, Shannon L Maude, et al.
The Lancet. Haematology|July 28, 2022
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issuesNina Worel, Mahmoud Aljurf, Chloe Anthias, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Transplantation and Cellular Therapy|November 1, 2023
Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell TransplantationLacey S Williams, Kirsten M Williams, Nancy Gillis, et al.
American Journal of Hematology|January 6, 2023
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemiaGuru Subramanian Guru Murthy, Brent R Logan, Stephanie Bo-Subait, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
The Journal of Clinical Investigation|April 5, 2017
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host diseaseDanny W Bruce, Heather E Stefanski, Benjamin G Vincent, et al.
Bone Marrow Transplantation|March 5, 2024
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Bone Marrow Transplantation|June 21, 2024
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Blood Cancer Discovery|January 12, 2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaMichael A Pulsipher, Xia Han, Shannon L Maude, et al.
The Lancet. Haematology|July 28, 2022
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issuesNina Worel, Mahmoud Aljurf, Chloe Anthias, et al.
Pageof 11